MCM
ARIA

Moore Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Moore Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-300,000
Closed -$2.06M – 498
2014
Q4 		$2.06M Hold
300,000
– – 0.07% 217
2014
Q3 		$1.62M Hold
300,000
– – 0.04% 297
2014
Q2 		$1.91M Buy
+300,000
New +$2.06M 0.05% 282

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Moore Capital Management's ARIA Position: Q4 2016 in Review

Moore Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 50,000 shares — an estimated $685K sold.

Moore Capital Management first reported a position in ARIA in Q2 2013 and held it in 3 quarters. The position peaked at $1.31M in Q2 2013. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Moore Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Moore Capital Management sold 50,000 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $685K.
  • Moore Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 3 quarters.
  • Moore Capital Management's Ariad Pharmaceuticals Inc position peaked at $1.31M in Q2 2013.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Moore Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.